




Terumo Corporation
Corporate Guide

An aerial photograph of a dense urban landscape, likely Tokyo, taken from a high vantage point. The city is filled with numerous skyscrapers and smaller buildings, their lights beginning to glow as the sun sets. The sky is a gradient of colors, from a deep blue at the top to a warm orange and red near the horizon where the sun is a bright, glowing orb. The overall atmosphere is serene and majestic.

One hundred years ago, as thermometer imports to Japan stopped due to World War I, Dr. Shibasaburo Kitasato and other physicians founded Terumo to meet the desperate need for production of quality thermometers in Japan.

These words appeared in the founding prospectus:

“As the health of the people of Japan depends on the spread of hygiene awareness, and as the health of the people is the key to national stability, this can be called an industry of national concern.”

The founders' mindset lives on in the Terumo Group Mission:
Contributing to Society through Healthcare.

Terumo contributes to the stability and development of society by striving for the health of all people and for the medical settings that support that health. That is our unchanging mission.

Terumo associates* will move forward for the next 100 years as well, bringing innovative products to patients and medical professionals around the world and helping to achieve a better society.

*At Terumo, employees are referred to as “associates” to emphasize the fellowship of working together as a team.

The background of the entire page is a photograph of a city skyline at sunset. The sky is a mix of orange, pink, and blue, with the sun low on the horizon. The city buildings are silhouetted against the sky, and some lights are visible. The overall mood is serene and professional.

Group Mission

Contributing to Society through Healthcare

We contribute to society by providing valued products and services in the healthcare market and by responding to the needs of patients and healthcare professionals.

Core Values

Respect — Appreciative of others

We show respect and appreciation toward associates, customers, and business partners. We value individuality and diverse cultures, and listen widely and carefully to different opinions and the voice of society.

Integrity — Guided by our mission

As associates of Terumo Group, responsible for life and health, we always act with sincerity and a sense of mission. Through our daily efforts, we build trust among all stakeholders.

Care — Empathetic to patients

We are mindful that everything we do ultimately connects us to patients. We strive to understand healthcare providers deeply and work together with them to give patients a better future.

Quality — Committed to excellence

To ensure safety and reliability in healthcare, we view each issue from a “gemba” perspective in order to find the optimal solution. As well as product quality, we pursue excellence in all we do, from product supply to customer care.

Creativity — Striving for innovation

We promote a mindset that embraces challenge for the future, and work with curiosity and passion. We respond to the needs of “gemba” by delivering products and services that create meaningful value in a timely manner.

Reconfirming our purpose, Contributing to healthcare for the next 100 years

We express our deepest condolences for those who have passed away due to COVID-19 and pray for the quick recovery of all people who have been infected.

Terumo has collaborated closely as a Group with medical professionals on the front lines battling COVID-19, while also working to keep healthcare going for patients with other illnesses. We have found in these efforts a reconfirmation of the true meaning of the Terumo Group Mission—Contributing to Society through Healthcare—and of our purpose as a corporate citizen—to solve the challenges of medical settings.

Many signs of the post-COVID era are appearing around the world; but even before this pandemic, the world of healthcare was in need of transformation. This global crisis has accelerated that transformation, and a paradigm shift is expected in healthcare. On September 17, 2021, Terumo celebrated its 100th anniversary. Looking ahead to the next 100 years, we will go beyond old paradigms to also create value in this new healthcare reality and contribute to medical settings and patients.

Takayoshi Mimura
Chairman of the Board

Shinjiro Sato
President and CEO

Effective April 1, 2022, Toshiaki Takagi has been appointed as Chairman of the Board and Takayoshi Mimura has been appointed as Director and Corporate Advisor.







For medical professionals who sustain life. For all people who desire the joy of life.

To provide each patient with optimal healthcare so they can live their best lives; this is the wish of most medical professionals, and it is also our wish.

Healthcare needs grow ever more diverse, and the way health is sustained is changing greatly.

Terumo has three companies encompassing eight global businesses that not only work to improve treatment efficacy and help reduce the mental and physical burdens on patients, but also provide products and solutions that help solve a variety of challenges in medical settings. We will walk alongside healthcare providers now and into the future toward realizing an ever greater contribution to society.

Terumo brings solutions of through three companies

Currently, the Terumo Group includes three companies and eight businesses that operate in over 160 countries and regions around the world, providing patients, a variety of medical settings, and the pharmaceutical industry with over 50,000 products and services. The Terumo mission includes not only bringing patients more effective and less burdensome treatments, but also providing medical professionals with safety and peace of mind so they can focus on giving care and supporting the research that will create future healthcare. We face and work to understand the problems of medical settings so we can provide new value.



Cardiac and Vascular Company

Realizing minimally invasive treatments in vascular intervention and cardiac surgery

The businesses of the Cardiac and Vascular Company involve the heart and lungs, which are basic to human life, and treatment of blood vessel diseases throughout the body. They provide interventional devices, which enable treatment by accessing blood vessels through a catheter to treat regions of the body including the heart and brain; oxygenators and heart-lung machines that sustain life in place of the heart and lungs during cardiac surgery; and surgical grafts and stent grafts that replace blood vessels damaged by disease. Each business of the company strives to bring about better treatment efficacy and reduce the burdens of patients while raising their quality of life.

TIS Division (Terumo Interventional Systems)

Neurovascular Division (MicroVention)

Cardiovascular Division (Terumo Cardiovascular)

Vascular Graft Division (Terumo Aortic)

value to medical settings and eight businesses.



Medical Care Solutions Company

Contributing to better patient care and transformation toward “yasashii*” medical care for everyone involved

As populations age, more patients require healthcare, and the number of patients with multiple or chronic illnesses is increasing, leading to higher healthcare expenditures. In addition, the global spread of the COVID-19 pandemic raised awareness of the importance of infection control. And as technology progresses, the need increases for individualized medicine tailored to each patient. To meet the diverse and complex needs of medical settings, we leverage our cultivated strengths to provide enhanced solutions that contribute to better patient care and healthcare transformation towards realizing friendly healthcare for everyone involved.

* Terumo calls medical care that brings benefits to patients, healthcare professionals, and all those involved in healthcare “yasashii” medical care, which includes medical safety, operational efficiency, and early discharge from the hospital.

Hospital Care Solutions Division

Life Care Solutions Division

Pharmaceutical Solutions Division




Blood and Cell Technologies Company

Sustaining blood transfusions worldwide, contributing to the advancement of blood and cell treatments

At blood centers, donated blood is processed into the components of platelets, plasma, and red blood cells. These are supplied to healthcare providers. Terumo collaborates with blood centers globally to provide collection and processing sets and other supplies for efficient blood processing. Additionally, the company provides devices that use centrifugation and separation technology to collect or remove specific blood components, enabling a variety of blood treatment solutions. In recent years, the fields of cell and gene therapy have advanced rapidly, and Terumo provides research institutions and pharmaceutical companies with instruments and services that enable high-quality, large-scale production of cell products to support the creation of new therapies.

**Expanding the potential of vascular treatment
to raise patient comfort**

Terumo Interventional Systems provides products that are used to treat diseases of the heart or lower limb blood vessels in vascular intervention (blood vessel care using a catheter); imaging used to view the interior of blood vessels; and interventional oncology used to perform chemotherapy to treat liver cancer. While pursuing better treatment efficacy, device usability and quality for interventional physicians, TIS also contributes to minimally invasive care that reduces patients' burdens.

**Vascular intervention****Access Devices**

Create the access point to insert a catheter into a blood vessel and the path to a lesion.

- Introducer sheath
- Guidewire
- Vascular closure device

Therapeutic Devices

Treat lesions inside a blood vessel using items such as stents and coils.

- Drug-eluting stent (DES)
- Peripheral stent
- Embolization coil system

Intravascular Imaging Systems


Use ultrasound or light to observe the surface or cross-section of blood vessel walls.

- Optical frequency domain imaging (OFDI) system
- Intravascular ultrasound (IVUS) system


Interventional Oncology**IO devices**

Perform chemotherapy via a catheter by accessing cancer cells through the hepatic artery.

- Micro balloon catheter
- Micro catheter
- Holmium microspheres
- Drug-elutable beads



Introducer sheath



Drug-eluting stent (DES)

Intravascular ultrasound (IVUS)
system

Micro balloon catheter

TOPICS**Peripheral care, and even chemotherapy—advancing transradial intervention**

Transradial intervention (TRI) is the procedure with the insertion of a catheter through the wrist to access blood vessels. Since the mid-1990s, Terumo has focused on developing devices for TRI and has supported its spread as a technique. TRI, which was initially used mostly to treat the arteries of the heart, has in recent years been expanded to areas including peripheral treatment and chemotherapy to treat liver cancer (interventional oncology). In 2019, Terumo leveraged expertise and technology cultivated over many years to launch a peripheral interventional treatment system. Used currently in the United States and Japan, it is slated for release throughout the world to help increase patient quality of life (QOL) and further contribute to medical cost efficiency.

**Revolutionizing neurovascular intervention
with unique technologies**

MicroVention pioneers the development of catheter-based, minimally invasive, neuroendovascular technologies that provide therapeutic advantages for neurovascular disorders. Terumo collaborates with this U.S. based subsidiary to provide innovative solutions to treat these diseases that can be devastating for patients, specifically ischemic stroke (a type of stroke caused by a blockage of blood flow within the brain), brain aneurysms (a weak, bulging area on the wall of an artery). Particularly a wide range of access device portfolio, including catheters and guidewires contributes healthcare professionals to gain easy access to the lesion to treat as well as improve patients' quality of life.

**Aneurysm Therapeutic Devices**

A brain aneurysm is a weak, bulging area on the wall of an artery. These devices treat an aneurysm that include filling the aneurysm sac or diverting the flow into the aneurysm.

- Hydrogel embolic coil
- Intrasaccular device
- Flow diverter

Embolization Devices

An arteriovenous malformation (AVM) or dural arteriovenous fistula (AVF) is an abnormal connection of blood vessels. These devices assist with treating these conditions or help prevent blood flow into blood vessels.

- Liquid embolic agent
- Occlusion balloon catheter

Aspiration Devices and Carotid Stent


Devices designed to treat blood clots within the neurovascular vessels that can tack down and contain plaque and/or remove clots.

- Aspiration catheter
- Clot retrieval device
- Carotid stent


Access Devices

These devices allow physicians to gain neuroendovascular access to the treatment areas in the brain.

- Micro catheter
- Guidewire
- Guiding catheter



Intrasaccular device



Flow diverter



Occlusion balloon catheter



Aspiration catheter

TOPICS**Expanding treatment potential, seeking technology that meets physician needs**

The degree of difficulty can vary when using X-ray to find and treat a lesion inside the blood vessels of the brain, depending on the position and shape of the lesion. For example, when an aneurysm with a wide opening occurs at the branch of two blood vessels, normal embolization coils might not be able to stop the flow of blood. In recent years, Terumo has developed an array of devices, including finely woven stents that close aneurysm openings, as well as pouch-like embolization devices made of shape-memory alloy, to treat a wide variety of cases. To support neurovascular therapy, Terumo has also sought out the most effective new technology, such as materials and designs tailored for X-ray visibility, so that the physicians performing procedures can get the highest performance.

Terumo Cardiovascular develops and manufactures medical devices that function outside the body in place of the heart and lungs during cardiac surgery; oxygenators which perform blood oxygen exchange in place of the lungs; ECMO systems that support heart and lung function for patients in emergency care; and devices that help to support surgery without stopping the heart. In collaboration with Terumo's HeartSheet division, which has produced world-first regenerative medicine products that are expected to provide new options for patients with serious heart failure, the division is also contributing to better patient quality of life through innovative technologies for heart disease patients.



Cardiovascular Division (Terumo Cardiovascular)

■ Cardiopulmonary Bypass System

Performs extracorporeal circulation and gas exchange in place of the patient's heart and lungs during cardiac surgery.

- Hollow fiber oxygenator with integrated arterial filter
- Heart-lung machine
- Continuous in-line blood parameter monitoring system

■ Extracorporeal Life Support System

Supports heart and lung functions in patients receiving emergency care due to acute heart attack or cardiac arrest.

- ECLS (Extracorporeal Life Support System) / ECMO (Extracorporeal Membrane Oxygenation) system

■ Off-pump Coronary Artery Bypass Surgery Products

Support the cardiac surgeon during surgery performed without stopping the heart.

HeartSheet Division

■ Products for Regenerative Medicine

Muscle tissue is taken from the thigh of a patient with severe heart failure. Skeletal myoblast cells from that tissue are cultured into sheet form and placed on the surface of the patient's heart. This provides a new treatment option to patients for whom recovery is not possible through drug or surgical therapies.



Hollow-fiber oxygenator



Extracorporeal membrane oxygenation (ECMO) system



Off-pump coronary artery bypass surgery products



Skeletal myoblast sheet

TOPICS

Building emergency ECMO production to fight COVID-19

ECMO technology can be used to treat patients with the novel coronavirus who suffer severe respiratory failure. To meet the sudden demand for ECMO systems amid the COVID-19 pandemic in Japan, Terumo built an emergency production line in its ME* Center site in Shizuoka Prefecture. An ECMO system comprises many parts and has a complex structure, so increasing its production would normally require a long period of time. Thanks also to cooperation from parts suppliers, Terumo succeeded in producing a quantity of ECMO units that would have normally taken a year in only a few months. Terumo will continue to make its best efforts to provide a stable supply of products to patients who need treatment.



Production of ECMO

Terumo Aortic is the group's vascular business, providing products including surgical grafts and stent grafts that are used by surgeons and interventional radiologists to treat patients with aortic disease, which includes thoracic and abdominal aneurysms and aortic conditions such as dissection. The company has a comprehensive product portfolio contributing to help save the lives of many patients in over 90 countries. Future plans include the development of products utilizing digital technology to deliver products optimized for individual patients, as Terumo Aortic continues the development of innovative and unique products to treat complex aortic pathologies.



Surgical Grafts

Used in surgery to replace diseased blood vessels or create bypass.

- Thoracic surgical graft
- Abdominal surgical graft



Thoracic surgical graft



Thoracic hybrid graft



Thoracic stent graft



Abdominal stent graft

Stent Grafts

Used in interventional treatment of aneurysms by implanting stented artificial blood vessels in affected areas to prevent rupture.

- Thoracic stent graft
- Abdominal stent graft

Hybrid Graft

Used as a combination of artificial blood vessel and stent graft to enable surgeons to treat patients in one procedure instead of the previous requirement for two separate procedures.

- Thoracic hybrid graft

TOPICS

Terumo Aortic's digital transformation strategy to help patients optimize their aortic care

The treatment of complex aortic disease is managed through the development of implantable devices such as surgical grafts and endovascular stent grafts. Terumo Aortic has the most comprehensive product portfolio in the aortic space and is currently developing digital solutions that will revolutionize aortic care for healthcare professionals and their patients. This year, the company has launched a digital platform in Europe that delivers healthcare professionals a simple, collaborative process for the management of customized endovascular device requests. These devices are tailored for the patient's specific anatomy and provide a solution when an off-the-shelf product is not suitable. This is part of a wider digital transformation strategy for Terumo Aortic with further solutions due to be launched in the near future.

Solving issues hospitals face by providing solutions to help improve the quality and safety of healthcare

The Hospital Care Solutions Division offers a variety of expertise to address the needs of those in medical care settings, including medical safety, in-facility infection prevention, and cost control. The division develops products that reduce the burden on patients and medical professionals and offer greater usability, provides operational support for medical equipment, and training programs for medical professionals.

By offering solutions to issues that are tough to solve simply by a single product, we contribute to improved treatment safety, workflow efficiency and better quality of life for patients.



Advanced Infusion System Products


Combine advanced infusion systems with digital health technologies to improve safety through drug administration efficiency and standardization.

- Infusion and syringe pump with system connectivity
- Pump monitoring system
- IV solution bag for safe administration
- Closed system drug transfer device (CSTD)
- Safety IV catheter ● Closed infusion system

Peritoneal Dialysis Products

Support peritoneal dialysis (PD) treatment through products that are easy to use and less burdensome on patients.

- Peritoneal dialysate ● Manually connected peritoneal dialysate exchange system
- Sterile tubing welder
- Automated peritoneal dialysis (APD) system



Syringe pump with system connectivity

Closed infusion system

IV solution bag for safe administration

Infection prevention and environmental control products

Provide infection control measures to medical professionals, including hand sanitizers and environmental control solutions for hospital rooms.

- Hand sanitizer ● Ultraviolet irradiation robot

Preoperative, Oncological Products

Contribute to issues of preoperative and oncology treatment with pain management solutions and prevention of complications.

- Sprayable adhesion barrier gel ● Analgesic
- Condensed liquid nutrition
- Highly condensed liquid nutrition (for oral intake)

TOPICS

Contributing to better hospital environments and infection control

The COVID-19 pandemic has resulted in renewed awareness of infection control in medical settings and also our daily lives. Many medical institutions face a wide range of difficult issues including how to establish their own infection control measures and operate devices appropriately. With the Medical Care Solutions Company at its core, Terumo offers comprehensive expertise for infection control and environmental control in hospitals. We aim to solve challenges in medical settings by proposing operating protocols for UV sterilization robots and providing training, as well as surface infrared body temperature screening.

Special infection control website (information for medical professionals; Japanese only)



Ultraviolet irradiation robot



Hand sanitizer



Infection control mascot

Life Care Solutions Division provides healthcare solutions optimized for individual patients living with diabetes and other chronic diseases. We contribute to improving patients' prognoses, preventing serious disease, and enhancing quality of life by creating new value for all patients.



Diabetes Care Products

Provide high-usability, minimal-pain products to be used for daily glucose management and insulin administration to contribute to better quality of life.

- Blood glucose self-monitoring system
- Continuous glucose monitoring system (Exclusive distribution in Japan only)
- Insulin patch pump
- Disposable needle for pen-injector



Insulin patch pump



Continuous glucose monitoring system



A series of vital measuring devices with communications functions



Thermometer / Infrared thermometer

Vital Sign Management Products


Provide timely management of patient vital signs efficiently and accurately with wireless connection technology.

- Blood glucose monitoring system
- Thermometer
- Blood pressure monitor
- Pulse oximeter

TOPICS

New Technology Helps Diabetes Patients Smile

Terumo has been providing innovative products in the diabetes field. In 2018, Terumo developed Japan's only patch-type insulin pump, and in 2019, Terumo started selling the US company Dexcom's continuous blood glucose monitor in Japan. In 2020, we signed a co-development agreement with the French company Diabeloop for an automated insulin delivery system (the AID system). We aim to further support diabetic patients through this AID system, which connects to a continuous blood glucose monitor which measures subcutaneous glucose concentration in real time to continuously deliver insulin from an insulin pump in response to the patient's condition.



Utilizing unique technologies to add value to pharmaceuticals and contribute to better drug delivery

Using its unique prefilled drug product technology, Terumo offers solutions to pharmaceutical companies by proposing new drug delivery devices. The division leverages its material technology optimized for the characteristics of each drug and utilizes advanced manufacturing technology to design and produce drug-device combination products. Through alliances with pharmaceutical companies, Terumo provides a total solution from clinical trial drug manufacture to full commercialization, contributing to safer and more certain delivery of drugs patients need.



Drug Development and Manufacture Partnering

Through partnerships with pharmaceutical companies, Terumo supports the entire process from prefilled device design through to commercial manufacturing.

- Prefilled syringe in auto-injector
- Prefilled syringe in safety device

Container Supply

Terumo provides highly usable devices made from materials optimized for use with biopharmaceuticals and vaccines.

- Ready-to-fill syringe
- Intradermal injection device

Drug Kit Administration Devices

Terumo provides administration devices for packaging with pharmaceuticals sold by pharmaceutical companies to contribute to greater efficiency in medical settings.

- Needles for drug kit



Prefilled syringe in auto-injector
Prefilled syringe in safety device



Ready-to-fill syringe



Needles for drug kit



Intradermal injection device

TOPICS

Strengthening production capacity to meet global needs

Terumo's drug-device combination products are produced by the Terumo Yamaguchi D&D headquarter factory, the Fujinomiya Pharmaceutical Factory, and the Kofu Pharmaceutical Factory. With material technology used in prefilled syringes and aseptic filling expertise, the Terumo Yamaguchi D&D headquarter factory, has been approved to produce prefilled syringes by the European EMEA, United States FDA, Japan PMDA, and other regulatory bodies. It currently manufactures a biosimilar product for autoimmune disease that is sold in Europe, as well as other combination products. Capacity expansion is in progress to raise production capacity to 3.5 times the volume it produced in 2016 and is expected to serve as a vital production site to drive business growth on a global scale.

Blood and Cell Technologies Company

Terumo Blood and Cell Technologies

Unlocking the potential of blood and cells
for patients and their quality of life

Blood and cells are indispensable in sustaining our lives, and at the same time, they hold the potential to treat cancer and other serious diseases. The Blood and Cell Technologies Company, which is headed by the subsidiary Terumo Blood and Cell Technologies, provides devices to safely and efficiently process donated blood into blood products and to collect blood components needed for transfusions and cell therapy. The company also offers automation and workflow efficiency solutions to support pharmaceutical company's manufacturing process for cell therapies. The company will continue to advance its unique technologies to provide patients with new treatment options.



Blood Centers Solutions

Realize better quality and efficiency in blood component collection and product preparation processes.

- Component collection system
- Automated blood processing system
- Blood bag sets with leukocyte filters
- Pathogen reduction system

Therapeutic Apheresis and Cell Collection

Collect blood components needed for treatment or remove unwanted components.

- Centrifugal apheresis system

Cell Processing

Process the cells needed for treatment or research efficiently to support cell therapy development and commercialization.

- Cell expansion system
- Cell therapy fill and finish system

Autologous Biologics

Separate, concentrate, and formulate a patient's own plasma, bone marrow or adipose tissue for treatment.

- Autologous biologics processing system



Blood bag sets with leukocyte filters



Centrifugal apheresis system



Cell expansion system



Autologous biologics processing system

TOPICS

Enter to source plasma market through collaboration

In April 2021, Terumo Blood and Cell Technologies and the U.S. company CSL Plasma began a collaboration in the source plasma collection. Plasma fractionation products are increasingly used in the treatment of patients who suffer serious symptoms due to genetic or immune diseases. Plasma contains over one hundred proteins, and plasma fractionation products are created by separating specific proteins by their physicochemical properties for use in treatments. Currently, clinical trials are underway for source plasma collection system, and Terumo is preparing for the United States Food and Drug Administration (FDA) clearance. Terumo will continue to focus its efforts into advancing blood and cell therapy technologies toward better healthcare for patients.

At a Glance

Fiscal year ended March 2021

Performance (consolidated)


Revenue

613.8 billion yen


Adjusted Operating Profit

115.9 billion yen

Revenue by Company



Revenue by Geographic Area



*As of April 2022, the General Hospital Company will be renamed the Medical Care Solutions Company, the Hospital Systems Division will be renamed Hospital Care Solutions Division and Life Care Solutions Division, while the Alliance Division will be renamed Pharmaceutical Solutions Division.

The percentage of revenue composition is rounded to the nearest whole number, and the total may not equal 100%.

Business / Organization Scale

Number of countries and regions where the Terumo Group's products are sold

More than **160**



Number of production bases

Japan **8**

Outside of Japan **24**



Number of consolidated subsidiaries

104



Number of products

More than **50,000**



Number of R&D bases

Japan **6**

Outside of Japan **17**



Human Resources

Number of associates (employees)

Terumo Group (consolidated)



26,482

Percentage of female associates¹



17.4%

Number / percentage of female managers²



69 / 8.1%

Terumo Corporation (non-consolidated)



5,247

Number / percentage of applicable male associates taking childcare leave³



89 / 63.1%

1, 2, 3 Scope: Terumo Corporation

Participation in External Initiatives

WE SUPPORT



Since 2012 Terumo has been committed to the UN Global Compact corporate responsibility initiative and its principles in the areas of human rights, labor, the environment, and anti-corruption.



FTSE4Good



FTSE Blossom Japan

Terumo is a constituent of the FTSE4Good Index Series and the FTSE Blossom Japan Index. (as of March 31, 2022)



SCIENCE
BASED
TARGETS

DRIVING AMBITIOUS CORPORATE CLIMATE ACTION

Terumo Group's target for reducing GHG emission in fiscal 2030 was approved to be aligned with "well-below 2 degrees pathway" by the Science-Based Targets initiative. Note: The target was raised to "1.5 degrees pathway" in November 2021 and has been submitted to the Science-Based Targets initiative for validation of the alignment with "1.5 degrees pathway".

2022 CONSTITUENT MSCI JAPAN ESG SELECT LEADERS INDEX

Terumo has been included as a constituent of the MSCI Japan ESG Select Leaders Index, a major index of Environmental, Social and Governance (ESG) investment. It is the first time the company has been selected for the index.

* The Inclusion of Terumo in any MSCI index, and the use of MSCI logos, trademarks, service marks or index names herein, do not constitute a sponsorship, endorsement or promotion of Terumo by MSCI or any of its affiliates. The MSCI indexes are the exclusive property of MSCI. MSCI and the MSCI index names and logos are trademarks or service marks of MSCI or its affiliates.



Terumo received the prestigious Prime Minister's Award out of the "5th Japan Medical Research and Development Awards" together with Shinhiro Takeda, Ph.D., President of Japan ECMOnet, a non-profit organization, for the "R&D, practical application and dissemination of ECMO".

Corporate Profile

Company Name	Terumo Corporation
Tokyo Office	Tokyo Opera City Tower, 3-20-2 Nishi-Shinjuku, Shinjuku-ku Tokyo 163-1450 Japan
Head Office	2-44-1 Hatagaya, Shibuya-ku, Tokyo, 151-0072 Japan
Founded	September 17, 1921
Share Capital	38.7 billion yen
Representative Directors	Toshiaki Takagi, Chairman of the Board Shinjiro Sato, President and CEO
Business	Manufacturing and sale of medical devices and pharmaceuticals
Stock Exchange Listing	Prime Market of Tokyo Stock Exchange (Code: 4543)



www.terumo.com

Our Activities

Fiscal year ended March 2021

Resolving Healthcare Challenges

Offering Structured Educational Programs to Medical Professionals around the World

Medical devices are only fully effective when used correctly. However, limited training opportunities in some countries lead to unmet demands from healthcare experts who need to continually advance their knowledge and techniques. To address this, Terumo is working to develop structured educational programs that enable healthcare professionals to deliver quality medical treatment. In 2002, Terumo established Terumo Medical Pranex, equipped with realistic and safe learning environments such as operating rooms and X-ray laboratories, identical to those in hospitals but without actual patients. Since then, the facility has provided training opportunities to physicians, nurses, and technicians from many countries. Terumo will continue offering professional development programs that meet global healthcare needs.



Associate helping to expand training programs

Creating a Diverse and Inclusive Workplace

Diversity and Inclusion

As one facet of the Company's diversity management efforts, Terumo promotes active participation by female associates. Globally, the Terumo Group endorses the goals of International Women's Day, and we hold internal events on a worldwide basis in recognition of the day.

In Japan, Terumo has started a project team to accelerate the promotion of active participation by women. That team is working throughout the organization to cultivate talent that can make decisions from a diverse range of perspectives. As an overall Group, Terumo is also working to raise diversity and inclusion through programs including female associate networking and other activities tailored to local characteristics.



Internal event at Terumo (Thailand) Co. Ltd.



The theme of the logo is "Overlap". The different sizes and colors of the overlapping characters express associates of diverse personalities shining together in a healthy environment that respects diverse values.

Health and Productivity Management ("Kenko Keiei")

As a company that contributes to healthcare, Terumo believes it is important to protect the health of its own associates.

With its senior management having committed its support to Kenko Keiei (Health and Productivity Management), Terumo encourages keen health awareness among all associates.

Terumo has defined four priority themes for Kenko Keiei:

1. reduction of ratio of smokers and ratio of associates diagnosed with metabolic syndrome,
2. early diagnosis and treatment of cancer to enable associates to return to the workplace,
3. women's health, and
4. encouragement of self-help.

A cross-organization team shares activity examples and issues to ensure a uniformly high level of activities. Kenko Keiei efforts are also promoted globally. Each region learns from the policies of others so that the Group as a whole progresses together with a feeling of unity.



Exercising on-site at Terumo Blood and Cell Technologies



Health examination being performed at Terumo Vietnam Co., Ltd.

Environmental Efforts

Mt. Fuji Reforestation Project

Terumo has two factories in the city of Fujinomiya in Shizuoka, Japan. Both take in groundwater from springs at the foot of Mt. Fuji for use in the production of medical devices, pharmaceuticals, and other products. Recognizing that the Company benefits from natural resources of Mt. Fuji, we launched the Terumo Mt. Fuji Reforestation Project in fiscal 2003 with the aim of restoring the natural forests in this area. This project involves the reforestation of parts of Mt. Fuji's forests where many trees have been destroyed by typhoons. Repopulating these areas with native tree species will help them become more resistant to future natural disasters and ensure that they can continue to serve as a source of groundwater. In fiscal 2011, three parties—Shizuoka Prefecture, a local forest owner, and Terumo—entered into an agreement called the Shizuoka Mirai-no-Mori (Future Forest) Supporter Pact. Under this agreement, we plant trees and maintain forested areas to create the Terumo Megumi-no-Mori reserve within the Fumoto district of Fujinomiya.



Terumo Mt. Fuji Reforestation activities

Serving Our Communities

Over 4 Million U.S. Dollars of Aid in Response to the Global COVID-19 Pandemic

Terumo has worked to proactively contribute to the prevention and treatment of the COVID-19 through donations of thermometers, ECMO systems, and other products, as well as monetary donations. In addition, the Group has donated to the WHO COVID-19 Solidarity Response Fund for research, infection control, treatment, and the supply of goods and information to medical professionals. These monetary and in-kind donations now exceed 4 million U.S. dollars. Terumo has worked for many years to solve the problems of medical providers and will continue going forward to contribute to the health and safety of the world.



Donation of thermometers, blood pressure monitors, and ECMO systems to a hospital in Wuhan, China



Supporting Early Diagnosis of Children with Congenital Heart Disease in India

It is said that nine out of 1,000 newborns in India have congenital heart disease (CHD), and early screening and diagnosis of the condition are key to saving many lives. Terumo Group subsidiary Terumo India Pvt. Ltd. (TIPL), which sells oxygenators and other devices used in cardiac surgeries, partners with a local NGO to conduct prescreening camps and support those diagnosed with the disease who need surgical correction. In fiscal 2019, TIPL was able to support 48 camps that screened 7,152 underprivileged and high-risk children susceptible to CHD, and it provided treatment to 93 children from these camps diagnosed with CHD.



Prescreening camp in India

100 Years of Terumo's History

Since its establishment, Terumo has continued advancing over the past 100 years, standing alongside patients and those in medical settings as we create new value.

Building the foundation for public health



Dr. Shibasaburo Kitasato and the establishment prospectus of the company that would later become Terumo

Courtesy of the Kitasato Institute archives


Reducing patients' physical strain

1982


Launch of the world's first microporous hollow fiber membrane oxygenator

1985

Launch of the angiographic catheter system in Japan and entry to the field of vascular intervention



Pursuing patient-friendly



1921


1960

1970

1980

1990

Controlling infection



1963

Launch of Japan's first disposable syringe

1969


Launch of Japan's first blood bag

1973

Launch of Japan's first intravenous solutions in soft plastic bags, based on the technology accumulated through the development of blood bags



Developing eco-friendly technologies



1983

Japanese launch of digital thermometers for hospitals

1985

Termination of mercury thermometer production and implementation of efforts to spread digital thermometers

Achieving greater and security in me



1999

Launch of prefilled syringes in Japan

History of the Terumo Group

■ **1921**

Foundation of Red Line Thermometer Corporation by a group of medical scientists led by Dr. Shibasaburo Kitasato for the purpose of manufacturing accurate clinical thermometers in Japan

■ **1936**

Change of company name to Jintan Thermometer Corporation

■ **1971**

Establishment of local affiliates in the U.S. and Europe (Belgium)

■ **1974**

Change of company name to Terumo Corporation

■ **1989**

Establishment of Shonan Center R&D facility in Japan

ly healthcare

1988

Launch of the peritoneal dialysis system in Japan

1993

Launch of the blood glucose monitor in Japan

2005

Launch of the world's thinnest injection needle for administering insulin and other medications in Japan

2006

Entry to neurovascular intervention therapy with embolization coils for treating brain aneurysms

2008

Launch of the drug-eluting coronary stent in Europe

2018

Launch of Japan's first insulin patch pump



2012

Launch of the hybrid graft in Europe

2016

Introduction of the autologous skeletal myoblast sheet, the world's first approved regenerative medicine for cardiac regenerative therapy in Japan



2016

Addition of world's first intrasaccular device to aneurysm treatment portfolio



2019

Launch of cell therapy fill and finish system

2020

Rebrand to "Blood and Cell Technologies Company" to reflect strengthening in the cell therapy field



2000

2010

2021

To the next 100 years

safety dical fields

2000

Introduction of the closed infusion system in Japan

2012

Introduction of the IV solution bag for safe administration in Japan



Supporting the development of medical technologies



Mid-1990s

Support for spreading TRI (transradial intervention: a coronary intervention technique with catheter insertion made from the radial artery in the wrist)

2002

Establishment of Terumo Medical Pranex, a training facility for medical professionals (Japan)

Providing a safe, efficient medical service platform



2012

Introduction of infusion systems that can be connected to hospital IT systems in Japan

2013

Introduction of a series of vital measuring devices with communications functions in Japan



■ **1999**

Cardiovascular division of 3M Company becomes part of Terumo, leading to establishment of Terumo Cardiovascular Systems Corp. in the U.S.

■ **2002**

Vascutek Ltd., a U.K. manufacturer of vascular grafts, joins Terumo Group

■ **2006**

MicroVention Inc., a U.S. neurovascular intervention device company, joins Terumo Group

■ **2011**

CaridianBCT Holding Corp. (current Terumo Blood and Cell Technologies), a global leader in the blood transfusion industry, joins Terumo Group

■ **2017**

Bolton Medical, Inc., a U.S. manufacturer of stent grafts for aortic treatment, joins Terumo Group

■ **2019**

Rebuilding Terumo Group Identity, newly creating Core Values

■ **2021**

Terumo Group's 100th anniversary



TERUMO CORPORATION

Tokyo Office

Tokyo Opera City Tower, 3-20-2 Nishi-Shinjuku, Shinjuku-ku, Tokyo 163-1450 Japan

Terumo Global Website www.terumo.com